AMACR, also known as P504S or alpha-methylacyl-CoA racemase, is an essential enzyme in the _-oxidation of branched-chain fatty acids and their derivatives. The enzyme is expressed in mitochondria and peroxisomes of numerous tissues such as liver, biliary tract, kidney and lung.
AMACR is overexpressed in patients with prostate cancer compared to benign tissue. Highest expression is found in localized prostate cancer and decreases as soon as the carcinoma forms metastases. It therefore makes sense to
use AMACR as a biomarker for the aggressiveness of a prostate carcinoma and its course. The antibody may be particularly helpful in the panel with HMW cytokeratin and / or p63.

[1] Jiang Z, Fanger GR, Woda BA et al. (2003): Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol. 34(8):792-6.
[2] Jiang Z, Woda BA, Rock KL et al. (2001): P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 25(11):1397-404.
[3] Varma M, Jasani B (2005): Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 47(1):1-16.
[4] Gologan A, Bastacky S, McHale T et al. (2005): Ageassociated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues. Am J Surg Pathol. 29(11):1435-41.
[5] Koseoglu E, Tuncel A, Balci M et al. (2018): Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer. Colomb Med (Cali). 49(2):164-168.
[6] Kuroda N (2014): Application of combined immunohistochemical panel of AMACR(P504S)/p63 cocktail, cytokeratin 5 and D2-40 to atypical glands in prostatic needle biopsy. Malays J Pathol. 36(3):169-73.
[7] Luo J, Zha S, Gage WR et al. (2002): Alphamethylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62(8):2220-6.